Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Work In Process (2016 - 2025)

Historic Work In Process for Corcept Therapeutics (CORT) over the last 10 years, with Q3 2025 value amounting to $14.2 million.

  • Corcept Therapeutics' Work In Process rose 8285.68% to $14.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.2 million, marking a year-over-year increase of 8285.68%. This contributed to the annual value of $7.8 million for FY2024, which is 539.29% down from last year.
  • Corcept Therapeutics' Work In Process amounted to $14.2 million in Q3 2025, which was up 8285.68% from $11.8 million recorded in Q2 2025.
  • Over the past 5 years, Corcept Therapeutics' Work In Process peaked at $14.9 million during Q1 2021, and registered a low of $6.7 million during Q2 2023.
  • Its 5-year average for Work In Process is $10.2 million, with a median of $8.7 million in 2023.
  • In the last 5 years, Corcept Therapeutics' Work In Process crashed by 4127.84% in 2023 and then soared by 8285.68% in 2025.
  • Quarter analysis of 5 years shows Corcept Therapeutics' Work In Process stood at $11.4 million in 2021, then tumbled by 31.64% to $7.8 million in 2022, then increased by 5.19% to $8.2 million in 2023, then fell by 5.39% to $7.8 million in 2024, then skyrocketed by 82.27% to $14.2 million in 2025.
  • Its Work In Process stands at $14.2 million for Q3 2025, versus $11.8 million for Q2 2025 and $7.0 million for Q1 2025.